dianhydrogalactitol has been researched along with Angiogenesis, Pathologic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, X; Huang, C; Huang, Y; Jiang, X; Li, F; Li, Y; Liang, Q; Liu, H; Wang, X | 1 |
1 other study(ies) available for dianhydrogalactitol and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Dianhydrogalactitol, a potential multitarget agent, inhibits glioblastoma migration, invasion, and angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dianhydrogalactitol; Glioblastoma; Human Umbilical Vein Endothelial Cells; Humans; Matrix Metalloproteinase 2; Neoplasm Invasiveness; Neovascularization, Pathologic; Proto-Oncogene Proteins; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Zebrafish | 2017 |